Latest Stent Stories
NATICK, Mass., Oct. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and effectiveness outcomes for the Epic(TM) Self-Expanding Nitinol Stent System in patients with obstructed iliac arteries. Results were presented today by Daniel Clair, M.D., FACS, principal investigator of the ORION trial and chairman of the Department of Vascular Surgery at The Cleveland Clinic...
MIAMI and WEBSTER, Texas, Oct. 22, 2012 /PRNewswire/ -- IDEV Technologies, Inc. (IDEV) today announced the presentation of consistent positive clinical outcomes of the SUPERA® Peripheral Stent System from its SUPERB pivotal U.S. clinical trial and SUPERA 500 long-term registry conducted in Germany. IDEV's data confirms a robust and consistent growing body of clinical evidence for SUPERA's highly differentiated, disruptive and proprietary stent design. The presentation was...
TEL AVIV, Israel, October 22, 2012 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (OTC: NSPR) announced updates on current commercial activities and unreviewed sales results for the period ended Sept. 30, 2012, the first quarter of its 2013 fiscal year. As previously announced, the Company changed its fiscal year to cover the period of July 1 to June 30. The Company said it renegotiated its product design licensing agreement with Svelte Medical...
NATICK, Mass., Oct. 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, which takes place October 22 - 26 in Miami, Florida. The clinical presentations will provide new insights on Boston Scientific research in coronary and peripheral artery disease, including aortic valve disease and...
WASHINGTON, Oct. 17, 2012 /PRNewswire/ -- Today, the Society for Cardiovascular Angiography and Interventions (SCAI) announced results from a new survey that found four out of five (81 percent) patients say their lives have changed for the better following angioplasty, a procedure to open blocked arteries and allow blood to circulate freely. Simultaneously, SCAI published a comprehensive review of research on quality of life following angioplasty and stenting. The paper offers...
HONG KONG, Oct. 16, 2012 /PRNewswire/ -- OrbusNeich today announced that multiple presentations of clinical data for the COMBO Dual Therapy Stent will take place next week at TCT 2012 in Miami Beach. The scientific sessions will feature cumulative results from the REMEDEE study (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt), a randomized trial of the COMBO Dual Therapy Stent versus a drug eluting stent, and data from the REMEDEE OCT and EGO COMBO...
DURHAM, N.C., Oct. 16, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced that data from clinical studies of its investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)) will be presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium to be held in Miami, Fla. on October 22 - 26, 2012. David Kandzari, M.D., Director of Interventional Cardiology and Chief Scientific Officer for the...
LAS VEGAS and WEBSTER, Texas, Oct. 10, 2012 /PRNewswire/ -- IDEV Technologies, Inc. today announced positive two-year clinical outcomes of the SUPERA® Peripheral Stent System from SUPERA 500, a long-term registry which was presented at the 10(th) VIVA Conference held in Las Vegas, Nevada by principal investigator, Dierk Scheinert, M.D., Chairman for the Center of Vascular Medicine at Park Hospital and Heart Center in Leipzig, Germany. "The SUPERA 500 registry reflects a...
LAS VEGAS and WEBSTER, Texas, Oct. 10, 2012 /PRNewswire/ -- IDEV Technologies, Inc. (IDEV) today announced positive clinical outcomes for its SUPERB pivotal clinical trial of its SUPERA® Peripheral Stent System. This Food and Drug Administration (FDA) Investigational Device Exemption (IDE) trial demonstrated the highest patency rates in peripheral stent trials for superficial femoral or proximal popliteal artery disease that has been publically reported. In addition, this is the...
WEBSTER, Texas, Sept. 27, 2012 /PRNewswire/ -- IDEV Technologies, Inc. (IDEV), an emerging global innovator in peripheral devices, today announced that Private Healthcare Australia has granted the Company a reimbursement code for the SUPERA(®) stent. The August 2012 Prostheses List was effective August 30, 2012. This is an important milestone as the Company continues to build a solid foundation in the Asia Pacific region. "Gaining the private reimbursement code opens a...
Latest Stent Reference Libraries
Interventional radiology (IR) is a special sub-operation under general radiology. It is used to find, diagnose and treat a disease in almost every body system. The process of interventional radiology is very noninvasive to help with the recovery and outcome of the procedure. It utilizes x-rays, CT, ultrasound, MRI, and other modes of imaging in order to direct tools in the body as well as a variety of catheters, narrow tubes, so that incisions can be minimalized. How it is Performed...
